DSGN•benzinga•
Design Therapeutics Releases Phase 1 Data For DT-168 Supporting Advancement Into Phase 2 Biomarker Trial For Patients With Fuchs Endothelial Corneal Dystrophy
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 1, 2025 by benzinga